Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10759861-B2
Publication Date
2020-09-01
Expiration Date
Abstract
The present invention provides anti-CD115 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic and diagnostic methods for the treatment of cancer, autoimmune, and other diseases.
Core Innovation
Anti-CD115 (CSF-1R/M-CSFR) monoclonal antibodies are described that include antagonist and neutralizing antibodies and antigen-binding fragments. The antibodies are generated using AlivaMab Mouse technology and are provided in chimeric and fully human variants, including IgG formats and antibody fragments.
The disclosed antibodies are characterized by binding to CSF-1R (CD115) and by functional inhibition of ligand interactions. The patent describes preventing CD115 dimerization, blocking binding of CSF-1 and IL-34 to CD115, and inhibiting ligand-induced phosphorylation, including p-Tyr formation associated with CD115 phosphorylation (p-CD115/p-MCSFR).
A lead mouse monoclonal antibody (CCK423A) is converted into fully human IgG1, IgG2, and IgG4 formats while retaining binding and neutralization potency. The disclosure further describes whole antibodies and fragments, including bispecific and multispecific formats, and provides compositions comprising the antibodies and physiologically acceptable carriers, along with recombinant polynucleotides, expression vectors, and host cells for antibody production.
Claims Coverage
The independent claim set is grounded in one independent claim covering two alternative CDR-anchored anti-CD115 antibody definitions. The inventive features are the heavy-chain and light-chain variable regions defined by specific SEQ ID NOs (alternative A or alternative B).
CD115 antibody defined by specified VHCDR and VLCDR SEQ ID NOs (alternative A)
An isolated anti-CD115 antibody (or an antigen-binding fragment) comprising a heavy chain variable region (VH) with VHCDR1 comprising SEQ ID NO: 444, VHCDR2 comprising SEQ ID NO: 876, and VHCDR3 comprising SEQ ID NO: 1308, and a light chain variable region (VL) with VLCDR1 comprising SEQ ID NO: 660, VLCDR2 comprising SEQ ID NO: 1092, and VLCDR3 comprising SEQ ID NO: 1524.
CD115 antibody defined by specified VHCDR and VLCDR SEQ ID NOs (alternative B)
An isolated anti-CD115 antibody (or an antigen-binding fragment) comprising a heavy chain variable region (VH) with VHCDR1 comprising SEQ ID NO: 450, VHCDR2 comprising SEQ ID NO: 882, and VHCDR3 comprising SEQ ID NO: 1314, and a light chain variable region (VL) with VLCDR1 comprising SEQ ID NO: 666, VLCDR2 comprising SEQ ID NO: 1098, and VLCDR3 comprising SEQ ID NO: 1530.
Claim coverage is directed to isolated anti-CD115 antibodies (or antigen-binding fragments) defined by specified combinations of VHCDR1/2/3 and VLCDR1/2/3 sequences via the recited SEQ ID NOs, with two alternative CDR-defined embodiments.
Stated Advantages
Documented Applications
Therapeutic and diagnostic use in oncology.
Therapeutic and diagnostic use in autoimmunity/inflammation.
Use in related diseases.
Interested in licensing this patent?